The SYNAPSE team is delighted to announce the launch of a new Innovative Medicines Initiative project, the European Health Data & Evidence Network (EHDEN), which will operate in Europe for the coming five years, 2018 – 2023.
The mission of EHDEN is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model. EHDEN will build on prior projects, such as EMIF and EHR4CR, in scaling their original intents and technologies.
Central to EHDEN will be the standardisation of health data to the OMOP common data model and the utilisation of analytical tools such as those developed by the international Observational Health Data Sciences and Informatics (OHDSI) open science collaboration (www.ohdsi.org), and others. A network of SMEs will be trained and certified to ensure high validity transformation of data to the common data model.
The EHDEN consortium comprises twenty-two partners, including academia, SMEs, patient associations, regulatory authorities and pharmaceutical companies, led by Erasmus Medical Centr (The Netherlands) and Janssen Pharmaceutica N.V. (Belgium).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
To read press release click here.
For more information please contact the project via enquiries@EHDEN.eu.
To follow on twitter click here.